— Know what they know.
Not Investment Advice
Also trades as: GMAB (NASDAQ) · $vol 127M · GMAB.CO (CPH) · $vol 55M · GE9.F (FSX) · $vol 0M

GNMSF OTC

Genmab A/S
1W: +13.0% 1M: +23.7% 3M: +51.8% YTD: +39.8% 1Y: +47.7% 3Y: +46.5% 5Y: -2.2%
$439.05
-8.50 (-1.90%)
 
Weekly Expected Move ±10.1%
$357 $402 $448 $493 $538
OTC · Healthcare · Biotechnology · Tech Score Buy · Power 76 · $27.0B mcap · 56M float · 0.0022% daily turnover · Short 43% of daily vol
Credit Risk of going bust: lower than 69% of companies Debt: 16.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $6.37 (down 99%), Genmab A/S would be worth roughly what it owes.
Total debt $5.27B against a stock market value of $27.47B.
Distance to default 7.47 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $2.71B (short-term plus half of long-term), stock volatility 35.1%; Altman Z'' 3.61. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

📊 Key Metrics

TTM
$4B
Revenue
-82.1% YoY
$782M
Net Income
-90.9% YoY
$869M
Free Cash Flow
-87.0% YoY
92.7%
Gross Margin
35.2%
Op. Margin
26.2%
Net Margin

💰 Income Flow

How revenue becomes profit

💵 Cash Flow

Where cash goes

🏦 Balance Sheet

Assets = Liabilities + Equity

📈 Financial Health

Profitability

ROE3.9%
ROA2.9%
ROIC11.9%

Valuation

P/E34.8
P/B4.6
EV/EBITDA15.2

Leverage

Debt/Equity0.89
Current Ratio2.46
Interest Cov.5.1x

Quality Scores

Piotroski F4/9
Altman Z2.90
Beneish M-4.42

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms